Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Follicular Lymphoma

Explore clinical trials studying Relapsed/Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

10 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Follicular Lymphoma trial results

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Boca Raton Clinical Research (BRCR) Global Plantation, Florida, United States
  • Indiana University and Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Hattiesburg Clinic Hattiesburg, Mississippi, United States
View all 169 locations
View Trial Details
Completed

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

NCT03939026

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

NCT05338879

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Regeneron Research Facility Graz, Austria
  • Regeneron Research Facility Caen, France
  • Regeneron Research Facility Paris, France
  • Regeneron Research Facility Pierre-Bénite, France
View Trial Details
Active, Not Recruiting

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Southern Cancer Center Mobile, Alabama, United States
  • Arizona Oncology Associates - Tuscon-Rusadill Road Tucson, Arizona, United States
  • TOI - Clinical Research Cerritos, California, United States
  • UCSF Fresno Clovis, California, United States
View all 204 locations
View Trial Details
Active, Not Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • Ucsf Fresno University of California San Francisco Fresno Fresno, California, United States
  • Kaiser Permanente Southern California Irvine, California, United States
  • Cancer and Blood Specialty Clinic Los Alamitos, California, United States
  • Los Angeles Cancer Network Los Angeles, California, United States
View all 270 locations
View Trial Details
Active, Not Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) Duarte, California, United States
  • Stanford Health Care Stanford, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • The University of Kansas Hospital Westwood, Kansas, United States
View all 52 locations
View Trial Details

Related conditions